U.S. Markets open in 7 hrs 39 mins

Biotech Breakout Candidates

HENDERSON, NV / ACCESSWIRE / December 24, 2018 / It’s been a busy week for biotech, here are a few companies in the news you should start researching.

Today we are highlighting:Delcath Systems, Inc. (DCTH), Adial Pharmaceuticals, Inc. (ADIL), Aduro BioTech, Inc. (ADRO), Geron Corporation (NASDAQ: GERN), and Amarin Corporation plc (NASDAQ: AMRN).

An interventional oncology company focused on treating liver cancers with some serious upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $2.589M, Share Price: $0.285), is in the news. They announced their Phase 3 clinical trial, raised $7 million, increased revenue 20% Y/Y, and were published in European Radiology among several other milestones.

The company has been making strides in their trials and expects to complete enrollment for their ocular melanoma trial in the first half of 2019.

In fact, DCTH just announced that the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.

Biotech in general looks ripe for a major comeback in the next few weeks and DCTH could be a major beneficiary.

____

Adial Pharmaceuticals, Inc. (ADIL) (Market Cap: $28.192M, Share Price: $4.30), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced that it has amended its license agreement with the University of Virginia Patent Foundation, d/b/a the University of Virginia Licensing & Ventures Group (UVA LVG). Pursuant to the amendment, Adial must commence its Phase 3 clinical trial of AD04 for the treatment of Alcohol Use Disorder (AUD) in 2019. Adial has previously announced that it plans to begin its Phase 3 clinical trial of AD04 in the first half of 2019.

____

Aduro BioTech, Inc. (ADRO) (Market Cap: 199.304M, Share Price: $2.51) announced that they were partnering up with Eli Lilly and Company (LLY) in a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases. Per Aduro's official press release regarding the matter, under the terms of the new agreement, Aduro will be compensated, upfront, with a payment of $12 million and ''will be eligible for development and commercial milestones up to approximately $620 million per product, as well as royalty payments in the single to low-double digits should Lilly successfully commercialize a therapy from the collaboration.''

____

Geron Corporation (GERN) (Market Cap: $182.919M, Share Price: $0.9816) announced that results from IMbark, a Phase 2 clinical trial of imetelstat treatment in Intermediate-2 or High-risk myelofibrosis (MF) patients who are relapsed or refractory to a Janus Kinase (JAK) inhibitor, were presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The oral presentation was made on December 3, 2018 by John Mascarenhas, M.D., Associate Professor of Medicine in the Myeloproliferative Disorders Program of the Tisch Cancer Institute, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, and an IMbark clinical investigator.

____

Amarin Corporation plc (AMRN) (Market Cap: $4.272B, Share Price: $13.23), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl) capsules, Amarin's first FDA approved product, are a unique, highly-pure and stable omega-3 fatty acid product available by prescription.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecutors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Regal Consulting, LLC